Neoplasia/BPH

	Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study. Front Oncol Zhang T, Li X, Zeng J, Xu M, Tie Y. PMID: 42453871 [PubMed - in process]
	Erratum to: Bhatia RK, Grieb SM, Anakwenze C, Rendle KA, Ngwa W, Grover S. Investigating the Uptake of Hypofractionation for Breast and Prostate Cancer in Sub-Saharan Africa: A Qualitative Study of Physician and Medical Physicist Perspectives. Adv Radiat Oncol. 2024;10:101683. Adv Radiat Oncol Bhatia RK, Grieb SM, Anakwenze C, Rendle KA, Ngwa W, Grover S. PMID: 42453791 [PubMed - in process]
	Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer. Cancer Manag Res Sui J, Chen Y, Jiang Y, He Q, Guo X. PMID: 42453701 [PubMed - in process]
	Driving precision medicine in testicular germ cell tumors: from preclinical models to clinical applications. Ther Adv Med Oncol Tavares NT, Liu MY, Henrique R, Jerónimo C, Weiss RS, Lobo J. PMID: 42453649 [PubMed - in process]
	Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. J Clin Med Carriere PP, Hassanzadeh CJ. PMID: 42452561 [PubMed]
	Association Between Physical Activity and Mortality in Men with or at Risk of Prostate Cancer: A Systematic Review. Healthcare (Basel) García-Miralles N, Martínez-García I, Marcilla-Toribio I, Herreros-Solano A, Fernández-Bravo-Rodrigo J, Patiño-Cardona S, Moreno-Charco E, Ortega-Armiñana AM, Gregori-Navarro M, Pascual-Morena C. PMID: 42451008 [PubMed]
	Immunometabolic Stress and Immune Suppression in Clear-Cell Renal Cell Carcinoma: Perspectives in Therapeutic Strategy. Int J Mol Sci Nguyen TV, Hsu T. PMID: 42450288 [PubMed - in process]
	Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation. Int J Mol Sci Mir MM, Wani JI, Mir R, Alharthi MH, Ayed A, Nandi P, Patel AA, Mallick AK, Alamri MMS, O'haj M, Khalid TBA, Jehangir A, Sonpol HMA, Senbel AM. PMID: 42450223 [PubMed - in process]
	Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer. Diagnostics (Basel) Sim KC, Kim MJ, Sung DJ, Park BJ, Han NY, Han YE, Cha SH. PMID: 42449730 [PubMed]
	Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications. Cancers (Basel) Mora-Garijo B, Rahman S, Xu H, Chatzkel J, Grass GD, Spiess PE, Li R. PMID: 42449716 [PubMed]
	Head-to-Head Comparison of [68Ga]Ga-PSMA-11 PET Interpreted with Non-Contrast CT Versus Excretory-Phase CT Urography in Biochemical Recurrence of Prostate Cancer. Cancers (Basel) Betech-Antar V, Rosales JJ, Mínguez F, Romera M, Fuertes L, Díez-Caballero F, Miñana-López B, Martinez-Monge R, Guillen EF, Rodríguez-Fraile M. PMID: 42449713 [PubMed]
	PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum. Cancers (Basel) Wang K, Hassanbhai DH, Teo RYA, Ong CSH, Lai KW, Koo SX, Yam WL, Tung JYM. PMID: 42449702 [PubMed]
	Safety and Treatment Discontinuation of Novel Hormonal Therapies in Metastatic Hormone-Sensitive Prostate Cancer: An Exploratory Real-World Study. Cancers (Basel) Millan-Ramos I, Zambudio-Munuera A, Herraez-Marcos M, Jimenez-Pacheco A, Gutierrez-Tejero F, Arrabal-Martin M, Arrabal-Polo MA. PMID: 42449686 [PubMed]
	The Central Role of Imaging in Renal Cell Carcinoma: A Comprehensive Review of Tumor Aggressiveness, Histology, and Radiomics. Cancers (Basel) Ivars A, Paño B, Puig J, Fresno M, Rodríguez L, Sebastia C, Nicolau C. PMID: 42449671 [PubMed]
	Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study. Cancers (Basel) Günalt, Bölek H, Kaplan Tüzün E, Usta S, Efil SC, Akkus AF, I, Kapar C, Sekmek S, Güzel HG, Guliyev M, Ozudogru T, Göksu SS, Sever ÖN, Arslan Ç, Karadurmu, Sendur MAN, Tural D, Özgüro, Yekedüz E, Ürün Y. PMID: 42449669 [PubMed]
	PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making. Cancers (Basel) Esperto F, Pischetola A, Bauckneht M, Passoni J, Testa A, Ferretti S, Puliatti S, Buti S, Scarpa RM, Campobasso D, Papalia R. PMID: 42449638 [PubMed]
	Risk Stratification in Renal Cell Carcinoma: A Narrative Review. Cancers (Basel) Dixon N, Wong V, Bicer F, Dason S, Singer EA. PMID: 42449624 [PubMed]
	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study. Cancers (Basel) Grimm MO, Grünwald V, Müller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, Schultze-Seemann W, Schulz H, Bögemann M, Grötzinger SW, Vaz L, Herber M, Bedke J. PMID: 42449619 [PubMed]
	Patient and Technology Selection for Focal Therapy in Prostate Cancer. Cancers (Basel) Dinckal M, Rodrigues Pessoa R, Pow-Sang J, Yu A. PMID: 42449614 [PubMed]
	Time-Dependent Diffusion MRI-Based Microstructural Mapping for Characterization of Cribriform and Intraductal Carcinoma Morphologies in Prostate Cancer: A Preliminary Study. Cancers (Basel) Wei Y, Yang S, Ren T, Wen Z, Li X, Ling J, Lin J, Guo Y, Zhao X, Wang H, Chen Y. PMID: 42449601 [PubMed]

Articles 1 - 20 / 189747

Page 1 of 9488



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy